DNA/RNA material contained in circulating extracellular vesicles secreted into the bloodstream by tumor cells captures cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a new study.Â
A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.
Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.Â
To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.Â
The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
A Hologic-commissioned survey from Gallup reveals that while most women across the United States understand the significance of regular health screenings, an estimated 72 million have missed or postponed a recommended screening.Â
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men.Â
The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.Â
Current screening protocols fail to catch a notable number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome and Lynch syndrome, which increase the risk of developing certain cancers. This issue is particularly pronounced among underrepresented minorities.Â
Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.
